The Biological Roles of CD47 in Ovarian Cancer Progression

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2024 Jun 4

PMID 38832992

Authors

Linan Xing

Zhao Wang

Yue Feng

Haixia Luo

Guijiang Dai

Lin Sang

Chunlong Zhang

Jianhua Qian

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is one of the most lethal malignant tumors, characterized by high incidence and poor prognosis. Patients relapse occurred in 65-80% after initial treatment. To date, no effective treatment has been established for these patients. Recently, CD47 has been considered as a promising immunotherapy target. In this paper, we reviewed the biological roles of CD47 in ovarian cancer and summarized the related mechanisms. For most types of cancers, the CD47/Sirpα immune checkpoint has attracted the most attention in immunotherapy. Notably, CD47 monoclonal antibodies and related molecules are promising in the immunotherapy of ovarian cancer, and further research is needed. In the future, new immunotherapy regimens targeting CD47 can be applied to the clinical treatment of ovarian cancer patients.

References

Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernandez-Pedro N, Cardona A, Cabrera-Miranda L . Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020; 9(7):2390-2402. PMC: 7131854. DOI: 10.1002/cam4.2882. View

Brown E, Frazier W . Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001; 11(3):130-5. DOI: 10.1016/s0962-8924(00)01906-1. View

Golubovskaya V, Berahovich R, Zhou H, Xu S, Harto H, Li L . CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. Cancers (Basel). 2017; 9(10). PMC: 5664078. DOI: 10.3390/cancers9100139. View

Jeanne A, Martiny L, Dedieu S . Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. Pediatr Res. 2016; 81(3):480-488. DOI: 10.1038/pr.2016.242. View

Sladek N . Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol. 2003; 17(1):7-23. DOI: 10.1002/jbt.10057. View

Jeanne A, Boulagnon-Rombi C, Devy J, Theret L, Fichel C, Bouland N . Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide. Clin Exp Metastasis. 2016; 33(7):637-49. DOI: 10.1007/s10585-016-9803-0. View

Zou H, Mou X, Zhu B . Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Glob Chall. 2023; 7(1):2200094. PMC: 9818137. DOI: 10.1002/gch2.202200094. View

Jaiswal S, Chao M, Majeti R, Weissman I . Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010; 31(6):212-9. PMC: 3646798. DOI: 10.1016/j.it.2010.04.001. View

Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J . Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer. Front Immunol. 2021; 12:768115. PMC: 8710451. DOI: 10.3389/fimmu.2021.768115. View

10.

Hamidi-Sofiani V, Rakhshi R, Moradi N, Zeynali P, Nakhaie M, Behboudi E . Oncolytic viruses and pancreatic cancer. Cancer Treat Res Commun. 2022; 31:100563. DOI: 10.1016/j.ctarc.2022.100563. View

11.

Yao S, Yin X, Chen T, Chen W, Zuo H, Bi Z . ALDH2 is a prognostic biomarker and related with immune infiltrates in HCC. Am J Cancer Res. 2021; 11(11):5319-5337. PMC: 8640816. View

12.

Jeanne A, Sick E, Devy J, Floquet N, Belloy N, Theret L . Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget. 2015; 6(20):17981-8000. PMC: 4627230. DOI: 10.18632/oncotarget.4025. View

13.

Roberts D, Isenberg J . CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes. Am J Physiol Cell Physiol. 2021; 321(2):C201-C213. PMC: 8424672. DOI: 10.1152/ajpcell.00175.2021. View

14.

Zhang X, Galardi E, Duquette M, Lawler J, Parangi S . Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res. 2005; 11(15):5622-30. DOI: 10.1158/1078-0432.CCR-05-0459. View

15.

Muaibati M, Abuduyilimu A, Zhang T, Dai Y, Li R, Huang F . Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer. Expert Rev Mol Med. 2023; 25:e6. DOI: 10.1017/erm.2023.3. View

16.

Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A . Role of CD47 in Hematological Malignancies. J Hematol Oncol. 2020; 13(1):96. PMC: 7364564. DOI: 10.1186/s13045-020-00930-1. View

17.

Cheng L, Zhang X, Tang J, Lv Q, Liu J . Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. Biomaterials. 2021; 275:120964. DOI: 10.1016/j.biomaterials.2021.120964. View

18.

Alemzadeh E, Dehshahri A, Izadpanah K, Ahmadi F . Plant virus nanoparticles: Novel and robust nanocarriers for drug delivery and imaging. Colloids Surf B Biointerfaces. 2018; 167:20-27. DOI: 10.1016/j.colsurfb.2018.03.026. View

19.

Singh P, Prasuhn D, Yeh R, Destito G, Rae C, Osborn K . Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release. 2007; 120(1-2):41-50. PMC: 2849971. DOI: 10.1016/j.jconrel.2007.04.003. View

20.

Jie X, Kong Y, Zhou G . [Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023; 54(3):455-461. PMC: 10475431. DOI: 10.12182/20230560101. View